BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16606472)

  • 21. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
    Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
    J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
    Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
    Anticancer Res; 2001; 21(4B):2983-7. PubMed ID: 11712798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
    PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
    Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
    Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
    Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
    Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion.
    Barbolina MV; Adley BP; Shea LD; Stack MS
    Cancer; 2008 Apr; 112(7):1632-41. PubMed ID: 18260155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
    Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
    BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
    Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
    Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
    Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum.
    Schlumbrecht MP; Xie SS; Shipley GL; Urbauer DL; Broaddus RR
    Mod Pathol; 2011 Mar; 24(3):453-62. PubMed ID: 21102415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
    Bergmann L; Miething C; Maurer U; Brieger J; Karakas T; Weidmann E; Hoelzer D
    Blood; 1997 Aug; 90(3):1217-25. PubMed ID: 9242555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.